Format

Send to

Choose Destination
Clin Infect Dis. 2011 Sep;53 Suppl 2:S33-55; quiz S56-8. doi: 10.1093/cid/cir475.

Appraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections--proceedings and data from the Gram-Negative Resistance Summit.

Author information

1
Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, 660 South Euclid Ave, Campus Box 8052, St Louis, MO 63110, USA. mkollef@dom.wustl.edu

Abstract

The emerging problem of antibiotic resistance, especially among Gram-negative bacteria (GNB), has become a serious threat to global public health. Very few new antibacterial classes with activity against antibiotic-resistant GNB have been brought to market. Renewed and growing attention to the development of novel compounds targeting antibiotic-resistant GNB, as well as a better understanding of strategies aimed at preventing the spread of resistant bacterial strains and preserving the efficacy of existing antibiotic agents, has occurred. The Gram-Negative Resistance Summit convened national opinion leaders for the purpose of analyzing current literature, epidemiologic trends, clinical trial data, therapeutic options, and treatment guidelines related to the management of antibiotic-resistant GNB infections. After an in-depth analysis, the Summit investigators were surveyed with regard to 4 clinical practice statements. The results then were compared with the same survey completed by 138 infectious disease and critical care physicians and are the basis of this article.

PMID:
21868447
PMCID:
PMC3161517
DOI:
10.1093/cid/cir475
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center